Clinical trials: Adult ADHD
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity
An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to assess the long-term safety and efficacy of three NRP104 doses of 30 mg, 50 mg, or 70 mg, administered at the same time daily, in the treatment of adults with ADHD.
- Conditions
- Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
- Trial name
- NCT00337285
- Testing
- Vyvanse (lisdexamfetamine dimesylate), NRP104
- Where
- 45 sites in United States
- Volunteers
- 349 people
- Sponsor
- New River Pharmaceuticals
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
This study evaluated the long-term safety and tolerability of centanafadine sustained-release (SR) tablets, administered twice daily (BID) in the treatment of adults with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT03605849
- Testing
- Centanafadine SR
- Where
- United States
- Volunteers
- 662 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder
CX717 in the Treatment of Adult ADHD
A Randomized, Double-Blind, Two-Period Crossover Study to Assess the Efficacy And Safety of the Ampakine® Compound, CX717, versus Placebo in Adults with Attention-Deficit Hyperactivity Disorder
- Trial name
- NCT03375021
- Testing
- CX717 200 mg, CX717 800 mg
- Volunteers
- 68 people
- Sponsor
- RespireRx
Attention Deficit Disorder With Hyperactivity
Safety of SPD465 in Treating Adults With ADHD.
The purpose of this study is to assess the safety and effectiveness of SPD465 in the treatment of ADHD. The study will also look at how SPD465 affects sleep.
- Trial name
- NCT00152035
- Testing
- Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.
- Volunteers
- 505 people
- Sponsor
- Shire
Attention Deficit/Hyperactivity Disorder
Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder
This study will evaluate the long-term safety of methylphenidate hydrochloride extended release in adults with attention deficit/hyperactivity disorder
- Trial name
- NCT01338818
- Testing
- Ritalin LA (methylphenidate hydrochloride extended release)
- Where
- 48 sites in United States, Belgium and 4 more
- Volunteers
- 299 people
- Sponsor
- Novartis Pharmaceuticals
Adult Attention Deficit Hyperactivity Disorder
Open-label Safety Study in Adults With ADHD
To evaluate the long-term safety and tolerability of SEP 225289 in adult subjects with Attention Deficit Hyperactivity Disorder (ADHD)
- Trial name
- NCT02160262
- Testing
- Dasotraline
- Where
- 65 sites in United States
- Volunteers
- 724 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention-Deficit/Hyperactivity Disorder
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.
The purpose of this study is to characterize the safety and tolerability of TAK-137 when administered as multiple oral doses in adults with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT02163915
- Testing
- TAK-137
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Takeda
ADHD, Anxiety
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety
- Conditions
- ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
- Trial name
- NCT06973577
- Testing
- Centanafadine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder, Comorbid Social Anxiety Disorder
Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder
To investigate the effect of atomoxetine hydrochloride in treating adults who have attention deficit hyperactivity disorder with comorbid social anxiety disorder
- Trial name
- NCT00190879
- Testing
- Atomoxetine hydrochloride
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 440 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Disorder With Hyperactivity
Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Trial 42603ATT3004 is an open-label extension study to clinical trial 42603ATT3002 (NCT00246220). In trial 42603ATT3002 the efficacy and safety of OROS methylphenidate was assessed in adult subjects with Attention Deficit…
- Trial name
- NCT00307684
- Testing
- double blind PR OROS methylphenidate, open label PR OROS methylphenidate
- Where
- 21 sites in France, Germany and 5 more
- Volunteers
- 155 people
- Sponsor
- Janssen-Cilag International NV
Attention Deficit Hyperactivity Disorder (ADHD)
A Long-term Trial of EB-1020 in Adult Patients With ADHD
The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in patients who have completed the double-blind trial (405-102-00112) conducted in Japan
- Trial name
- NCT06926829
- Testing
- EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg
- Where
- Japan
- Volunteers
- 180 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Attention Deficit Hyperactivity Disorder
A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)
The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with ADHD.
- Trial name
- NCT00443391
- Testing
- ABT-089
- Where
- 21 sites in United States
- Volunteers
- 141 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Attention Deficit Hyperactivity Disorder
Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)
The primary objective of this clinical study is to assess overall safety and tolerability as measured by discontinuation rate due to adverse events in doses up to 120 mg/day in relation to global clinical studies in adult…
- Trial name
- NCT00636818
- Testing
- Atomoxetine
- Where
- 11 sites in China, South Korea and 1 more
- Volunteers
- 45 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Deep Transcranial Magnetic Stimulation (DTMS) as a Treatment for Attention Deficit Hyperactivity Disorder (ADHD) in Adults
The aim of the study is to assess the effect of left or right high-frequency DTMS on ADHD symptoms, cognitive performance and decision-making ability of ADHD adults, and to compare this to the effect of sham DTMS on ADHD adults
- Trial name
- NCT01196910
- Testing
- treatment by HLPFC coil
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- Brainsway
Attention-Deficit/Hyperactivity Disorder
The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
This is a phase 2, randomized, multi-center, double-blind, 3-period and 3-treatment crossover study designed to evaluate the safety and duration of efficacy of SPD465 (50 or 75 mg) compared with placebo and an immediate release…
- Trial name
- NCT00928148
- Testing
- SPD465, Immediate Release Amphetamine Salt
- Volunteers
- 86 people
- Sponsor
- Shire
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy of SPD465 in Adults With ADHD
The purpose of the study is to evaluate how safe and how well SPD465 works compared to placebo in adults with ADHD. It is hypothesized that SPD465 will achieve an extended duration of clinical benefit.
- Trial name
- NCT00202605
- Testing
- Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity
Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the safety and effectiveness of NRP104 administered as a daily morning dose (30, 50, and 70mg/day) compared to placebo in adults (18-55 years of age inclusive) diagnosed with moderate to…
- Conditions
- Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
- Trial name
- NCT00334880
- Testing
- NRP104
- Where
- 48 sites in United States
- Volunteers
- 420 people
- Sponsor
- New River Pharmaceuticals
ADHD
Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate efficacy, safety and tolerability of metadoxine (MG01CI) extended release formulation for the treatment of adults diagnosed with ADHD
- Trial name
- NCT01243242
- Testing
- Metadoxine (MG01CI)
- Where
- 2 sites in Israel
- Volunteers
- 120 people
- Sponsor
- Alcobra Ltd.
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
This study evaluated the efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with ADHD. Participants either received a twice-daily dose of centanafadine sustained-release tablets, or…
- Trial name
- NCT03605836
- Testing
- Centanafadine SR
- Where
- United States
- Volunteers
- 590 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
ADHD, Attention Deficit Disorder
Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial
This study measures the safety and efficacy of repeated low dose MM120 as treatment for ADHD in adults: a multi-center, randomized, double-blind, placebo-controlled
- Trial name
- NCT05200936
- Testing
- MM120
- Where
- 2 sites in Netherlands, Switzerland
- Volunteers
- 53 people
- Sponsor
- Definium Therapeutics US, Inc.